Physician profile
Muhammad Umer
NPI 1114239944
$2,916.48
in general payments reported to CMS, 2019-2025
13 companies · $133 in 2025
The $133 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.00 · 2020: $13.84 · 2022: $112 · 2023: $715 · 2024: $1,870 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143 · Travel and Lodging: $1,021 · Education: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.33 |
| Travel and Lodging | $1,021.29 |
| Education | $552.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,999.09 | 2023-2024 | Gallant, Ensite |
| Medical Device Business Services, INC. | $238.70 | 2023 | Carto 3 |
| Medtronic, INC. | $155.52 | 2023-2025 | Symplicity G3, Ffrangio, Onyx Frontier |
| Astrazeneca Pharmaceuticals Lp | $149.28 | 2023-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.14 | 2022 | |
| Glaxosmithkline, LLC. | $73.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.61 | 2023 | |
| Boston Scientific Corporation | $32.44 | 2023 | |
| Chiesi USA, INC. | $24.80 | 2023 | Kengreal |
| Actelion Pharmaceuticals US, INC. | $22.91 | 2023 | Opsumit, Uptravi |
| Lilly USA, LLC | $18.83 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $14.32 | 2023 | Xarelto |
| Amarin Pharma, INC. | $13.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Umer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.